← Retour au Screener

Sector: Santé
Open in Terminal → VIRLive chart · Key metrics · News · Smart money

Vir Biotechnology, Inc.

VIR Small Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

7,99 €
-1.51% aujourd'hui
52W: 3,63 € – 10,16 €
52W Low: 3,63 € Position: 66.7% 52W High: 10,16 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
23.59x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
1,3 Md €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-47.69%
Rentabilité des capitaux propres
Beta
1.64
Sensibilité au marché
Positions vendeuses
11%
% du flottant vendu à découvert
Volume moyen
1,761,933
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
9 analysts
Avg. Price Target
18,80 €
+135.32% upside
Target Range
13,95 € – 26,15 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 367 Exchange: NMS

Vir Biotechnology, Inc. en bref

Vir Biotechnology, Inc. (VIR) is currently trading at 7,99 € with a market capitalization of 1,3 Md €. The 52-week range spans from 3,63 € to 10,16 €; the current price is 21.4% below the yearly high.

💰 Dividende

Vir Biotechnology, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

9 analystes évaluent Vir Biotechnology, Inc. (VIR) au consensus : Achat Fort. L'objectif de cours moyen est de 18,80 €, soit un potentiel de +135.32% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 13,95 € à 26,15 €.

Vir Biotechnology, Inc. : la thèse d'investissement en détail

Vir Biotechnology, Inc. (VIR) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 135.32% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 11% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 135.32% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Strong Buy
  • Bilan solide avec faible endettement (D/E 11.76)
Points faibles
  • Positions vendeuses élevées (11%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
8,26 €
-3.38% vs. cours
MM 200 jours
6,48 €
+23.28% vs. cours
Sous le plus haut 52s
−21.4%
10,16 €
Au-dessus du plus bas 52s
+120.2%
3,63 €

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

Risque de marché (Bêta)
1.64 · Élevé
Évolue plus que le marché global
Positions vendeuses
11% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
11.76 · Faible
Dette totale / capitaux propres

The data points to above-average price swings, elevated short interest (11%).

Trading Data

50-Day MA: 8,26 €
200-Day MA: 6,48 €
Volume: 5,982,028
Avg. Volume: 1,761,933
Short Ratio: 11.51
P/B Ratio: 1.67x
Debt/Equity: 11.76x
Free Cash Flow: -187 366 172 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Vir Biotechnology, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut